New Analyses from Three Trials in Obstructive HCM Support Findings from Previously Published Data on MYQORZO™ (aficamten) ...

SOME PETS WERE RESCUED FROM HOMES. ALL NEW AT FIVE. AND FOR YOUR HEALTH, THE MEDICAL RESEARCHERS AT THE UNIVERSITY OF PITTSBURGH ARE AT IT AGAIN. THEY PUBLISHED RESEARCH LAST WEEK FOCUSING ON A WAY TO ...

Please provide your email address to receive an email when new articles are posted on . There was a significant independent link between angiotensin-converting enzyme inhibitor use and all-cause ...

Enzymes help with specific functions that are vital to the operation and overall health of the human body. They help speed up chemical reactions and are essential for respiration, digestion, muscle ...

A next-generation drug tested in yeast was found to extend lifespan and slow aging by influencing a major growth-control pathway. Researchers also uncovered an unexpected role for agmatinases, enzymes ...

An expert discusses how rilzabrutinib’s covalent reversible binding mechanism provides a favorable safety profile with only manageable grade 1 to 2 toxicities and no cardiovascular or bleeding ...

Rilzabrutinib, a BTK inhibitor, is approved for ITP, showing significant efficacy in improving platelet response and reducing bleeding symptoms. The LUNA 3 study demonstrated rilzabrutinib's ...

BRUIN CLL-314 is the first-ever head-to-head Phase 3 study versus a covalent BTK inhibitor to include treatment-naïve patients INDIANAPOLIS, July 29, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: ...

Pirtobrutinib met the primary endpoint of response rate non-inferiority, favoring pirtobrutinib with a nominal P-value for superiority < 0.05 Progression-free survival data was immature, but trending ...

A recent study from Stanford Medicine that "totally surprised" researchers highlighted what could be a promising approach to slowing Parkinson’s disease progression. The research, published in the ...

In a new study published in Science Signaling titled, “Restoration of striatal neuroprotective pathways by kinase inhibitor treatment of Parkinson’s linked-LRRK2 mutant mice,” researchers from ...